Clinical trial
Clinical Benefit of Topoisomerase Downregulation
NCT00250094 · New Mexico Cancer Research Alliance, Other · Completed
Key facts
| NCT number | NCT00250094 |
|---|---|
| Title | Clinical Benefit of Topoisomerase Downregulation |
| Official title | Clinical Benefit of Topoisomerase Downregulation: A Phase I Pilot Study |
| Lead sponsor | New Mexico Cancer Research Alliance, Other |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | Topotecan and VP16 |
| Enrollment | 15 |
| Start date | May 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Mar 1, 2006 |
| First posted | Nov 7, 2005 |
| Last update posted | Sep 7, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: